Horizon Therapeutics PLC (NASDAQ:HZNP) Director James Samuel Shannon sold 15,500 shares of the firm’s stock in a transaction that occurred on Thursday, September 12th. The stock was sold at an average price of $26.59, for a total transaction of $412,145.00. Following the completion of the transaction, the director now owns 15,500 shares in the company, valued at approximately $412,145. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.
NASDAQ:HZNP traded down $0.09 during trading hours on Friday, hitting $26.34. The company had a trading volume of 838,735 shares, compared to its average volume of 1,792,526. The company has a market capitalization of $4.93 billion, a PE ratio of 14.39, a price-to-earnings-growth ratio of 1.55 and a beta of 0.77. The stock has a 50-day moving average price of $26.34 and a 200 day moving average price of $25.61. Horizon Therapeutics PLC has a 52 week low of $16.56 and a 52 week high of $29.44. The company has a debt-to-equity ratio of 0.90, a current ratio of 2.20 and a quick ratio of 2.12.
Horizon Therapeutics (NASDAQ:HZNP) last released its quarterly earnings results on Wednesday, August 7th. The biopharmaceutical company reported $0.52 earnings per share for the quarter, beating the consensus estimate of $0.38 by $0.14. The business had revenue of $320.60 million for the quarter, compared to analysts’ expectations of $296.27 million. Horizon Therapeutics had a net margin of 5.90% and a return on equity of 30.33%. The firm’s revenue for the quarter was up 5.9% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.48 earnings per share. Analysts anticipate that Horizon Therapeutics PLC will post 1.6 EPS for the current fiscal year.
Several research analysts have recently issued reports on HZNP shares. Cowen set a $35.00 target price on shares of Horizon Therapeutics and gave the stock a “buy” rating in a report on Wednesday, August 7th. Guggenheim initiated coverage on shares of Horizon Therapeutics in a report on Thursday. They issued a “buy” rating and a $36.00 target price on the stock. Piper Jaffray Companies set a $33.00 price target on shares of Horizon Therapeutics and gave the company a “buy” rating in a report on Monday, August 26th. ValuEngine cut shares of Horizon Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, September 5th. Finally, BidaskClub cut shares of Horizon Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, September 6th. Four research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. Horizon Therapeutics presently has a consensus rating of “Buy” and an average target price of $33.00.
Institutional investors have recently made changes to their positions in the business. Manchester Capital Management LLC purchased a new position in Horizon Therapeutics during the first quarter valued at $41,000. New York State Teachers Retirement System purchased a new position in Horizon Therapeutics during the second quarter valued at $55,000. Steward Partners Investment Advisory LLC purchased a new position in Horizon Therapeutics during the second quarter valued at $76,000. FNY Investment Advisers LLC purchased a new position in Horizon Therapeutics during the second quarter valued at $80,000. Finally, Tower Research Capital LLC TRC lifted its position in Horizon Therapeutics by 384.1% during the second quarter. Tower Research Capital LLC TRC now owns 3,389 shares of the biopharmaceutical company’s stock valued at $82,000 after buying an additional 2,689 shares during the period. 86.29% of the stock is owned by institutional investors and hedge funds.
About Horizon Therapeutics
Horizon Therapeutics Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. Its orphan and rheumatology marketed medicines include KRYSTEXXA, a medicine for the treatment of uncontrolled gout; RAVICTI for use as a nitrogen-binding agent for chronic management of adult and pediatric patients; PROCYSBI for nephropathic cystinosis, a rare and life-threatening metabolic disorder; ACTIMMUNE for chronic granulomatous disease; RAYOS for the treatment of multiple conditions, rheumatoid arthritis; BUPHENYL tablets for oral administration and BUPHENYL powder for oral, nasogastric, or gastrostomy tube administration; and QUINSAIR, a formulation of the antibiotic drug levofloxacin for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis.
See Also: Trade Deficit
Receive News & Ratings for Horizon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.